All articles by Drug Target Review

  • shutterstock_2566377981
    News

    DNA-based system delivers targeted cancer drugs via biomarker logic

    2026-04-01T13:57:00Z

    Researchers at the University of Geneva have developed a DNA-based drug delivery platform that uses molecular logic gates to identify cancer cells through dual biomarker recognition. The system activates cytotoxic agents only when both tumour markers are present, offering enhanced specificity over current antibody–drug conjugates while enabling deeper tissue penetration and multi-drug combinations.

  • shutterstock_2497328305
    News

    Human antimicrobial peptide dermcidin shows antiviral activity against influenza

    2026-03-31T14:05:00Z

    Researchers at Fisabio Foundation have discovered that dermcidin, an antimicrobial peptide naturally present in human sweat, exhibits antiviral activity against influenza by binding to viral haemagglutinin and preventing cell fusion, opening new possibilities for innate immunity-based therapeutics.

  • shutterstock_2718496257
    News

    Mirrored molecules target disordered proteins in Alzheimer’s disease

    2026-03-31T09:28:00Z

    Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.

  • Screenshot 2026-03-31 103146 - final copy square
    Report

    CRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions

    2026-03-31T09:16:00Z

    Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

  • The microelectrode array with neural networks from different origins (cell line)
    News

    Scientists scale up neural organoid studies for drug testing

    2026-03-30T13:34:00Z

    Researchers at King’s College London have developed a hybrid neural organoid approach that addresses longstanding limitations in scalability, reproducibility and longitudinal analysis. By dissociating 3D organoids and culturing pooled cells on microelectrode arrays, the team created 2D networks that retain cellular diversity whilst enabling consistent, long-term tracking of neural activity across parallel cultures.

  • Low-Res_260316 HOBIT_Jones-103833
    News

    Implantable ‘living pharmacy’ device produces multiple drugs inside the body

    2026-03-30T09:54:00Z

    Scientists have developed an implantable device that acts as a ‘living pharmacy’, using engineered cells to continuously produce multiple therapeutic biologics inside the body. The wireless system, which generates its own oxygen supply, maintained stable drug levels for 30 days in preclinical studies.

  • shutterstock_2662715185
    News

    $13.9M UCLA study maps autism and schizophrenia biology for drug discovery

    2026-03-27T13:06:00Z

    A $13.9 million UCLA-led research programme will use CRISPR gene editing and ‘cell villages’ to systematically map the molecular differences underlying autism and schizophrenia, addressing the absence of medicines targeting the biological roots of both conditions.

  • Artificial,Intelligence,,Ai,In,Biotechnology,Analyzing,Dna,Helix,And,Genetic
    Interview

    Computational design drives new generation of synthetic promoters

    2026-03-26T14:21:00Z

    SynGenSys applies computational design strategies to engineer synthetic promoters with predictable performance characteristics for therapeutic and manufacturing applications. Professor David James discusses how tissue-specific regulatory elements are designed from genomic data to enable precise control of gene expression in contexts ranging from NK cell immunotherapy to biologic production.

  • Computer,Screen,With,Molecular,Modelling,Software,With,Animated,Chemical,And
    Interview

    Physics-based modelling offers a new way to study drug targets

    2026-03-26T14:15:00Z

    Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state. 

  • shutterstock_2480692527
    News

    Haem signalling pathway identified as key driver of T cell exhaustion

    2026-03-26T13:51:00Z

    University of Lausanne researchers have identified a molecular mechanism explaining how cancer-fighting T cells become exhausted in tumours, offering a potential route to improve CAR T therapies through proteasome modulation during cell manufacturing.

  • shutterstock_2630279391
    News

    COPD drug roflumilast may help fight breast cancer lung metastasis

    2026-03-26T11:25:00Z

    University of Colorado Anschutz Cancer Center scientists have uncovered how metastatic breast cancer cells exploit pulmonary repair pathways to establish tumours in the lungs. 

  • shutterstock_658210339
    News

    Scientists link IVNS1ABP gene to new ageing disorder

    2026-03-26T09:43:00Z

    An international research team has identified a previously unknown genetic disease characterised by premature ageing and progressive neurological decline. Using genome sequencing combined with induced pluripotent stem cell technology, scientists traced the condition to a mutation in the IVNS1ABP gene and uncovered disrupted actin dynamics during cell division as the underlying pathological mechanism.

  • shutterstock_2141712691
    News

    New evidence links autoantibodies to Long COVID

    2026-03-26T09:29:00Z

    Dutch researchers have demonstrated that IgG autoantibodies from Long COVID patients can induce persistent pain-like hypersensitivity in mice, with effects lasting at least two weeks. The study identifies distinct biological subgroups and suggests that autoimmune mechanisms may drive the condition’s diverse symptomatology, opening avenues for targeted immunotherapies. 

  • shutterstock_2660489315
    News

    AI discovers peptide that eases ulcerative colitis symptoms

    2026-03-26T09:03:00Z

    Researchers at First Hospital of Jilin University have used machine learning to identify antimicrobial peptides with therapeutic potential for ulcerative colitis. The AI-driven approach screened over 6,000 candidates, identifying a lead peptide that demonstrated superior efficacy to standard treatments in preclinical models by reducing inflammation, restoring gut barrier integrity and selectively modulating the microbiome.

  • shutterstock_2630725489
    News

    CD47 protein found to drive glioblastoma growth

    2026-03-26T08:41:00Z

    University of Adelaide researchers have discovered that CD47, a protein known for helping cancer cells evade immune detection, also directly promotes glioblastoma growth and invasion through a novel molecular pathway involving ROBO2 stabilisation.

  • shutterstock_1975691972
    News

    Blocking protein pathway may slow Huntington’s disease

    2026-03-24T15:43:00Z

    Researchers have identified a previously unknown cellular mechanism involving tunnelling nanotubes and the protein SLC4A7 that enables toxic huntingtin to spread directly between neurons, offering new therapeutic targets for Huntington’s disease.

  • shutterstock_2272147503
    News

    Biomarker discovery may improve schizophrenia treatment

    2026-03-24T15:31:00Z

    Northwestern University scientists have identified a circulating brain protein biomarker that is significantly reduced in schizophrenia patients and developed a synthetic therapeutic that corrected abnormal brain activity in preclinical models, offering hope for treating the disorder’s debilitating cognitive symptoms.

  • shutterstock_2705694081
    News

    Gut microbes found to drive chronic kidney disease

    2026-03-24T15:21:00Z

    A newly discovered feedback loop between impaired kidney function and gut bacteria may drive disease progression through toxic compound production. UC Davis researchers have identified a potential therapeutic target to interrupt this damaging cycle.

  • T,Cells,Attacking,Cancer,Cells,3d,Illustration
    News

    New AI-designed T-cell engager LGTX-101 to be presented at AACR in San Diego

    2026-03-18T14:47:08Z

    LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.

  • Probiotic,Bacteria,,Lactobacillus,,,3d,Illustration.
    News

    Probiotic bacteria successfully attacks tumours in preclinical models

    2026-03-18T10:00:00Z

    Engineered probiotic bacteria that can deliver cancer-fighting drugs directly to tumours have shown promising results in mice, offering a potential new approach to targeted cancer therapy.